AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00935311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-712 Extended-release
Description: ABT-712 extended-release tablet
Study NCT00935311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocodone/Acetaminophen Immediate-release
Description: Hydrocodone/acetaminophen immediate-release tablet
Study NCT00935311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet
Study NCT00935311 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT00935311 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet
Study NCT04979676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy
Description: Experimental psychotherapy based on the cognitive model for social anxiety disorder, applied individually and remotely to participants fulfilling inclusion criteria.
Study NCT04979676 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Therapy
Description: Experimental psychotherapy based on the cognitive model for social anxiety disorder, applied individually and remotely to participants fulfilling inclusion criteria.
Study NCT04979676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Compassion-focused Therapy
Description: Experimental psychotherapy based on the principles of the compassion-focused model, applied individually and remotely to participants fulfilling inclusion criteria.
Study NCT04979676 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Compassion-focused Therapy
Description: Experimental psychotherapy based on the principles of the compassion-focused model, applied individually and remotely to participants fulfilling inclusion criteria.
Study NCT04979676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Experimental psychotherapy based on the principles of the acceptance and commitment model, applied individually and remotely to participants fulfilling inclusion criteria.
Study NCT04979676 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Acceptance and Commitment Therapy
Description: Experimental psychotherapy based on the principles of the acceptance and commitment model, applied individually and remotely to participants fulfilling inclusion criteria.
Study NCT02735668 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Shoulder Conventional Exercises
Description: The protocol consists in:~• Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment:~* Mobilisation Joint Exercises.~* Isometrics and Resisted Exercises (elastic bands).
Study NCT02735668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal Physiotherapy
Description: The protocol consists in:~* Dry Needling in active myofascial trigger points related to shoulder joint (optimal hygiene and disinfection before and after needling). Special care in muscles located in the arm in women with axillary node dissection.~* If Upper Limb Neural Tension Test is positive, neurodynamic techniques will be included.
Study NCT02735668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scapular exercises
Description: The protocol consists in:~Scapula-focused exercises: based on evaluation of scapular dyskinesis and Kinetic Medial Rotation Test as well as inherent characteristics of each woman, individualized scapular exercises were prescribed based on a motor control approach with emphasis on obtaining a neutral scapular orientation.
Study NCT02735668 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education
Description: The protocol consists in:~Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases.
Study NCT02735668 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Education
Description: The protocol consists in:~Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases.
Study NCT01053494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: massage therapy
Description: Undergo massage therapy
Study NCT01053494 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01053494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT01053494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01053494 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01053494 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention by caregiver
Description: Undergo massage by caregiver
Study NCT01053494 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard follow-up care
Description: Undergo standard follow-up care
Study NCT02466282 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography-guided PCI with bioresorbable vascular scaffold
Description: Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
Study NCT02466282 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: optical coherence tomography-guided PCI with bioresorbable vascular scaffold
Description: Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
Study NCT03525691 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low flow Extracorporeal CO2 removal
Description: Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)
Study NCT03525691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low flow Extracorporeal CO2 removal
Description: Low flow Extracorporeal CO2 removal using a 0.67 m² membrane oxygenator (Lilliput 2) and a specific circuit (HP-X) mounted on a RRT monitor (PrismafleX)
Study NCT04407988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate plus Letrozole
Description: pyrotinib(400 mg once daily) + Letrozole (2.5 mg once daily)
Study NCT03386357 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: A (pembrolizumab+RT)
Description: Pembrolizumab (200mg absolute, q3w) combined with radiotherapy (12x3Gy) of one, two or three metastases. Only metastases that perspectively require radiotherapy will be treated. The irradiated tumor volume must be at least 10cm³. Radiotherapy of brain metastases is not allowed.
Study NCT03386357 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: B (pembrolizumab)
Description: Pembrolizumab (200mg absolute, q3w)
Study NCT00395317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firategrast 150 mg
Description: 150 mg tablet
Study NCT00395317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Firategrast 300 mg
Description: 300 mg tablet
Study NCT05100277 — intervention group
Intervention type: GENETIC
Intervention: Oncotype DX® Assay
Description: After surgery, tumoral tissue was used to perform Oncotype Dx®. Patients were evaluated and therapy recommendations - adjuvant chemotherapy (CT) plus hormone therapy (HT) or HT alone - were captured before and after revealing the test results. Results from TAILORx10 were used to guide decisions for or against CT for individual patients. Changes in treatment recommendations were obtained.
Study NCT05100277 — intervention group
Intervention type: OTHER
Intervention: Cost
Description: Changes in treatment costs were estimated from Pérola Byington Hospital.
Study NCT03423004 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: the sample will be taken by superficial cutaneous biopsy in psoriasic patients
Study NCT04186637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALPN-202
Description: Multiple dose levels and dose regimens of ALPN-202 will be administered
Study NCT01353209 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg daily for twelve months
Study NCT01353209 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo given daily for twelve months
Study NCT01934777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid plus Vitamin E plus choline
Description: DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
Study NCT01934777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo pearls
Description: placebo
Study NCT03718559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban Monotherapy
Description: Taking edoxaban (Lixiana™, Daiichi-Sankyo Inc.) 60mg once daily. The dose of edoxaban will be reduced to 30mg once daily in patients with estimated creatinine clearance 15≤CrCL≤50mL/min by Cockcroft-Gault equation or weight is ≤60kg.
Study NCT02177461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study NCT03718559 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban plus Single Antiplatelet Agent
Description: Type of antiplatelet agent is dependant upon the investigator's discretion, but aspirin 100mg once daily or clopidogrel 75mg once daily was recommended.
Study NCT02939586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haemodiafiltration post-dilution model
Description: Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months, 1 month wash-out (HD) and cross-over to the other dialysis model- eg. HDF (2months) and switch to HD for 2 months, with 1 month washout period (using standard HD). Haemodialysis post-dilution model will be delivered using fresenius 5008 machine. Prescription for HDF post-dilution will be comparable to HD.
Study NCT02939586 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Haemodialysis
Description: Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HD (2months) and switch to HDF for 2 months, with 1 month washout period (using standard HD). Haemodialysis treatment will be delivered using fresenius 5008 machine. treatment time/parameters may vary depends on individual prescription.
Study NCT01860833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: time of treatment 14 days
Study NCT01860833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: time of treatment 14 days
Study NCT01860833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: time of treatment 14 days
Study NCT04031859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetylsalicylic acid
Description: It's a VTE risk stratification tool or procedure that will be used after total knee replacement (TKR) to help surgeons in choosing the tailored VTE prophylaxis according to patients' specific VTE risk, this tool will stratify the TKR-patient in one of three risk-groups: Low high risk who will be prescribed Aspirin upon hospital discharge as extended VTE prophylaxis post TKR surgery, or moderate high risk group who will be prescribed oral anti coagulant (like rivaroxaban) as extended prophylaxis, and the last group is very high risk group who will be prescribed parenteral anticoagulant ( like Enoxaparin) plus compression devices.
Study NCT01770574 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReproBone
Description: Artificial bone graft is inserted as a wedge in the calcaneal lengthening osteotomy
Study NCT01770574 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: calcaneal lengthening
Description: Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
Study NCT01770574 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: calcaneal lengthening
Description: Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
Study NCT01073449 — intervention group
Intervention type: PROCEDURE
Intervention: In-hospital follow-up of cardiac device
Description: Electrical measures taken during normal follow-up and clinical status of the patient
Study NCT02665182 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Up-positioning of the testes
Description: Patients in the experimental arm are asked to elevate their testes during the treatment.
Study NCT02342223 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Voluma
Study NCT00662974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perineal massage with Wheat Germ Oil during the second stage of labor
Description: 30 ml of oil applied during labor
Study NCT00203164 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rasagiline mesylate
Description: rasagiline mesylate 1 mg oral once daily
Study NCT05336578 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Platelet rich fibrin application
Description: PRFs were prepared by obtaining10 ml blood samples from each patinet and inserting them in a centrifuge device (Intra-Lock International Inc., Boca Raton, USA), under 2700 rpm for 12 min using high speed. The platelet-rich fibrin layer remaining between the acellular plasma and red blood cells in the tube was separated with the help of scissors or a scalpel. After the tooth extraction in the experimental group PRF located to the extraction socket.
Study NCT03018691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPA-15406
Study NCT03018691 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study NCT03623763 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic tests of blood samples
Description: Five milliliters of peripheral venous blood will be (after 8-12 hours of fasting) from each participant and will be collected into Human Tube Serum Gel - C/A for ELISA. All blood samples will be collected in August and January. Serum levels of 25(OH) VD and TNF-α, IFN-γ, IL-4 and IL-6 will be detected by ELISA technique
Study NCT00909506 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control: Receive placebo pill once every evening on 1\~2 weeks.~Receive placebo pill in every morning and evening on 3\~24 weeks (twice a day).
Study NCT00909506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1\~2 weeks.~Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3\~24 weeks.
Study NCT00909506 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1\~2 weeks. (Dose-escalate)~Receive oral metformin 500 mg in every morning and evening on 3\~24 weeks (metformin 500 mg \* twice a day = 1000 mg per day).
Study NCT03647826 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind Power Intervention
Description: The intervention has a total sample of 110 schoool classes, which are devided in two arms: Mind Power Intervention Group 1 or Mind Power Intervention Group 2
Study NCT02637765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Increased Physical Activity
Description: Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
Study NCT00479336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061 7.5mg
Description: 7.5mg, 1 tablet a day
Study NCT00479336 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OPC-41061 placebo
Description: placebo, 1 tablet a day
Study NCT00479336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061 15mg
Description: 15mg, 1 tablet a day
Study NCT00479336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41601 30mg
Description: 30mg, 1 tablet a day
Study NCT00108862 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strategy: Immediate ART
Description: The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is efavirenz (EFV) 600 mg (1 tablet orally), emtricitabine (FTC) 200 mg (1 capsule orally), and tenofovir disoproxil fumarate (TDF) 300 mg (1 tablet orally) daily. Substitutions with other locally available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
Study NCT00108862 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strategy: Deferred ART
Description: The intervention is the strategy of initiating ART either after 8-12 weeks of RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is EFV 600 mg (1 tablet orally), FTC 200 mg (1 capsule orally), and TDF 300 mg (1 tablet orally) daily. Initiation outside of these windows, on a case by case basis, is permitted at the discretion of the site investigator. Substitutions with other locally available U.S. FDA-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
Study NCT01426958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: afatinib
Description: standard therapeutic dose
Study NCT01426958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir + afatinib
Description: simultaneous intake of ritonavir and afatinib on second treatment day
Study NCT01426958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir + afatinib
Description: on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet
Study NCT04609631 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: 24-form Tai Chi will be performed for 12 weeks. Each session contains a warm-up period (10 minutes), a Tai Chi period (40 minutes) and a cool-down period (10 minutes).
Study NCT04609631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT will be performed once a week for 12 weeks. Each session lasts for 1 hour.
Study NCT05992792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet
Description: Internet connection in their mobile phone and WI-Fi. Participants push message cancer prevention from the recomendations ECAC. Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
Study NCT05992792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Whithout internet
Description: Second randomization for received 2 notifications (push) per week or frequency of 7 SMS notifications per week.
Study NCT04002414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sufficient physical activity
Description: Physical activity at the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
Study NCT04002414 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Insufficient physical activity
Description: Physical activity less than the recommended levels by the US Health and Human Services Department: 75 minutes a week of vigorous activity or 150 minutes a week of moderate activity.
Study NCT01734551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Start at 0.4mg/kg/day (divided every 3-4 hours, given with feeds. Dose may be increased 25% of initial dose until symptoms are stable, up to 1 mg/kg/day.~Once stable for 72 hrs, weaning may begin (decrease 10% of max dose, every other day). When total dose is \<0.1mg/kg/day, may discontinue.
Study NCT01734551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: Initial dose is 5 mcg/kg/day (divided every 3-4 hrs, given with feeds). Will increase 25% of initial dose every 12-24 hrs until stable, up to 12 mcg/kg/day. Dose is unchanged for 72 hours once stable, then may decrease by 10% every other day. If re-escalation is required, the previous dose may be used with 72 hours for stabilizing.
Study NCT01358227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PR104
Description: Dose escalation of PR104 to determine maximum tolerated dose for weekly administration